Consolidated Portfolio Review Corp’s iShares iBonds Dec 2027 Term Corporate ETF IBDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-50,520
Closed -$1.23M – 198
2025
Q3
$1.23M Buy
50,520
+3,003
+6% +$72.8K 0.15% 148
2025
Q2
$1.15M Buy
47,517
+3,687
+8% +$89K 0.16% 145
2025
Q1
$1.06M Buy
43,830
+5,263
+14% +$127K 0.17% 137
2024
Q4
$924K Buy
38,567
+5,714
+17% +$138K 0.15% 164
2024
Q3
$801K Buy
32,853
+1,922
+6% +$46.3K 0.18% 145
2024
Q2
$734K Buy
30,931
+4,487
+17% +$106K 0.17% 148
2024
Q1
$629K Buy
+26,444
New +$630K 0.17% 143

Other funds holding IBDS

Consolidated Portfolio Review Corp's IBDS Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of iShares iBonds Dec 2027 Term Corporate ETF (IBDS) in Q4 2025, closing a stake of 50,520 shares — an estimated $1.23M sold.

Consolidated Portfolio Review Corp first reported a position in IBDS in Q1 2024 and held it in 7 quarters. The position peaked at $1.23M in Q3 2025. 415 funds tracked by Wall St. Rank hold IBDS as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining iShares iBonds Dec 2027 Term Corporate ETF position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 50,520 iShares iBonds Dec 2027 Term Corporate ETF shares in Q4 2025, an estimated $1.23M.
  • Consolidated Portfolio Review Corp first reported a position in iShares iBonds Dec 2027 Term Corporate ETF in Q1 2024 and held it in 7 quarters.
  • Consolidated Portfolio Review Corp's iShares iBonds Dec 2027 Term Corporate ETF position peaked at $1.23M in Q3 2025.
  • 415 funds tracked by Wall St. Rank held iShares iBonds Dec 2027 Term Corporate ETF as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.